Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAYHIA: ianalumab versus placebo in previously treated warm autoimmune hemolytic anemia
2024-510635-21-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in warm autoimmune hemolytic anemia (wAIHA) comparing Ianalumab with Placebo (2 arms). Primary endpoint: Durable response. Planned start May 2023; status: authorised.
02
Drugs
ianalumab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on 2024-510635-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510635-21-00.